

AMENDMENTS TO THE CLAIMS

Claims 1-20 cancelled.

21. (Currently Amended) A pharmacological composition comprising:

- (A) at least one biologically-active agent; and
- (B) at least one carrier compound having the formula



or a salt thereof, wherein

Ar is a phenyl or naphthyl substituted with at least one of C₁-C₅ alkyl, C₂-C₄ alkenyl, -F, -Cl, -OH, -SO₂, -COOH or -SO₃H;

R⁷ is selected from the group consisting of C₄ to C₂₀ alkyl, C₄ to C₂₀ alkenyl, phenyl, naphthyl, (C₁ to C₁₀ alkyl)phenyl, (C₁ to C₁₀ alkenyl)phenyl, (C₁ to C₁₀ alkyl)naphthyl, (C₁ to C₁₀ alkenyl) naphthyl, phenyl (C₁ to C₁₀ alkyl), phenyl (C₁ to C₁₀ alkenyl), naphthyl (C₁ to C₁₀ alkyl) and naphthyl (C₁ to C₁₀ alkenyl);

R⁷ is optionally substituted with C₁ to C₄ alkyl, C₁ to C₄ alkenyl, C₁ to C₄ alkoxy, -OH, -SH and -CO₂R⁹ or any combination thereof;

R⁷ is optionally interrupted by oxygen, nitrogen, sulfur or any combination thereof;

R⁸ is selected from the group consisting of hydrogen, C₁ to C₄ alkyl, C₁ to C₄ alkenyl, hydroxy, and C₁ to C₄ alkoxy; and

R⁸ is optionally substituted with C₁ to C₄ alkyl, C₁ to C₄ alkenyl, C₁ to C₄ alkoxy, -OH, -SH and -CO₂R⁹ or any combination thereof;

R⁹ is hydrogen, C₁ to C₄ alkyl, or C₁ to C₄ alkenyl;

with the proviso that the compounds are not substituted with an amino group in the position alpha to the acid group.

22. (Currently Amended) The composition of claim 21 wherein Ar is a phenyl substituted ~~phenyl~~ with at least one of C₁-C₅ alkyl, C₂-C₄ alkenyl, -F, -Cl, -OH, -SO₂, -COOH or -SO₃H.

23. (Original) The composition of claim 21, wherein Ar is a phenyl substituted with -Cl.

24. (Original) The composition of claim 21, wherein Ar is a phenyl substituted with -F.

25. (Currently Amended) The composition of claim 23, wherein R⁷ is selected from the group consisting of C₄ to C₂₀ alkyl, C₄ to C₂₀ alkenyl, (C₁-C₁₀ alkyl)phenyl, and phenyl (C₁ to C₁₀ alkyl).

26. (Original) The composition of claim 23, wherein R⁷ is C₄-C₂₀ alkyl.

27. (Original) The composition of claim 26, wherein R⁷ is not substituted or interrupted.

28. (Original) The composition of claim 27, wherein R⁸ is hydrogen.

29. (Previously Presented) The composition of claim 21, wherein the biologically active agent comprises at least one peptide, hormone, polysaccharide, mucopolysaccharide, carbohydrate, or lipid.

30. (Original) The composition of claim 29, wherein the biologically active agent is a peptide.

31. (Original) The composition of claim 29, wherein the biologically active agent is a mucopolysaccharide.

32. (Previously Presented) The composition according to claim 21, wherein the biologically active agent comprises human growth hormone, bovine growth hormone, growth hormone-releasing hormone, an interferon, interleukin-1, interleukin-II, insulin, heparin, low molecular weight heparin, calcitonin, erythropoietin, atrial natriuretic factor, an antigen, a monoclonal antibody, somatostatin, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, vasopressin, cromolyn sodium, vancomycin, desferrioxamine, parathyroid hormone, an antimicrobial, an antifungal agent or a combination thereof.

33. (Currently Amended) The composition according to claim 32, wherein said biologically-active agent comprises human growth hormone, an interferon, insulin, heparin, low

molecular weight heparin, calcitonin, erythropoietin, cromolyn sodium, parathyroid hormone, an antimicrobial, an antigen or a combination thereof.

34. (Original) The composition according to claim 33, wherein said biologically-active agent comprises human growth hormone.

35. (Original) The composition according to claim 33, wherein said biologically-active agent comprises insulin.

36. (Original) The composition according to claim 33, wherein said biologically-active agent comprises heparin.

37. (Original) The composition according to claim 33, wherein said biologically-active agent comprises low molecular weight heparin.

38. (Original) The composition according to claim 33, wherein said biologically-active agent comprises calcitonin.

39. (Original) The composition according to claim 33, wherein said biologically-active agent comprises cromolyn sodium.

40. (Original) The composition according to claim 33, wherein said biologically-active agent comprises parathyroid hormone.

41. (Previously Presented) A dosage unit form comprising

- (A) a pharmacological composition according to claim 21; and
- (B)
 - (i) an excipient,
 - (ii) a diluent
 - (iii) a disintegrant
 - (iv) a lubricant,
 - (v) a plasticizer,
 - (vi) a colorant,
 - (vii) a dosing vehicle, or
 - (viii) any combination thereof.

42. (Original) The dosage unit form according to claim 41, comprising a tablet, a capsule, or a liquid.

43. (Original) The dosage unit form according to claim 41, wherein said dosing vehicle is selected from the group consisting of water, 1,2-propane diol, ethanol, and any combination thereof.

44. (Currently Amended) A method for preparing a pharmacological composition, said method comprising mixing:

- (A) at least one biologically-active agent;
- (B) at least one carrier compound having the formula



wherein

Ar is a ~~substituted~~ phenyl or naphthyl substituted with at least one of C₁-C₅ alkyl, C₂-C₄ alkenyl, -F, -Cl, -OH, -SO₂, -COOH or -SO₃H;

R⁷ is selected from the group consisting of C₄ to C₂₀ alkyl, C₄ to C₂₀ alkenyl, phenyl, naphthyl, (C₁ to C₁₀ alkyl)phenyl, (C₁ to C₁₀ alkenyl)phenyl, (C₁ to C₁₀ alkyl)naphthyl, (C₁ to C₁₀ alkenyl) naphthyl, phenyl (C₁ to C₁₀ alkyl), phenyl (C₁ to C₁₀ alkenyl), naphthyl (C₁ to C₁₀ alkyl) and naphthyl (C₁ to C₁₀ alkenyl);

R⁷ is optionally substituted with C₁ to C₄ alkyl, C₁ to C₄ alkenyl, C₁ to C₄ alkoxy, -OH, -SH and -CO₂R⁹ or any combination thereof;

R⁷ is optionally interrupted by oxygen, nitrogen, sulfur or any combination thereof;

R⁸ is selected from the group consisting of hydrogen, C₁ to C₄ alkyl, C₁ to C₄ alkenyl, hydroxy, and C₁ to C₄ alkoxy; and

R⁹ is hydrogen, C₁ to C₄ alkyl, or C₁ to C₄ alkenyl;

with the proviso that the compounds are not substituted with an amino group in the position alpha to the acid group; and

- (C) optionally a dosing vehicle.

45. (Previously Presented) A method for administering a biologically-active agent to an animal in need of said agent, said method comprising administering orally to said animal a composition as defined in claim 21.

46. (Previously Presented) A method for administering a biologically-active agent to a mammal in need of said agent, said method comprising administering orally to said mammal a composition as defined in claim 21.

47. (New) The composition of claim 21, wherein R^7 is selected from the group consisting of C_4 to C_{20} alkyl, C_4 to C_{20} alkenyl, $(C_1-C_{10}$ alkyl)phenyl, and phenyl (C_1 to C_{10} alkyl) and wherein R^8 is hydrogen.

48. (New) The composition of claim 21, wherein R^7 is C_4 - C_{20} alkyl and wherein R^8 is hydrogen.

49. (New) The composition of claim 21, wherein R^7 is not substituted or interrupted and wherein R^8 is hydrogen.

50. (New) The composition of claim 21, wherein R^7 is selected from the group consisting of C_4 to C_{20} alkyl, C_4 to C_{20} alkenyl, $(C_1-C_{10}$ alkyl)phenyl, and phenyl (C_1 to C_{10} alkyl) and wherein R^8 is C_1 - C_4 alkyl.

51. (New) The composition of claim 21, wherein R⁷ is C₄-C₂₀ alkyl and wherein R⁸ is C₁-C₄ alkyl.

52. (New) The composition of claim 21, wherein R⁷ is not substituted or interrupted and wherein R⁸ is C₁-C₄ alkyl.

53. (New) The composition of claim 21, wherein R⁷ is selected from the group consisting of C₄ to C₂₀ alkyl, C₄ to C₂₀ alkenyl, (C₁-C₁₀ alkyl)phenyl, and phenyl (C₁ to C₁₀ alkyl).

54. (New) The composition of claim 21, wherein R⁷ is C₄-C₂₀ alkyl.

55. (New) The composition of claim 21, wherein R⁷ is not substituted or interrupted.

56. (New) The composition of claim 21, wherein R⁸ is hydrogen.

57. (New) The composition of claim 21, wherein R⁸ is C₁-C₄ alkyl.

58. (New) The composition of claim 22, wherein R⁷ is selected from the group consisting of C₄ to C₂₀ alkyl, C₄ to C₂₀ alkenyl, (C₁-C₁₀ alkyl)phenyl, and phenyl (C₁ to C₁₀ alkyl) and wherein R⁸ is hydrogen..

59. (New) The composition of claim 22, wherein R^7 is C_4 - C_{20} alkyl and wherein R^8 is hydrogen.

60. (New) The composition of claim 22, wherein R^7 is not substituted or interrupted and wherein R^8 is hydrogen.

61. (New) The composition of claim 22, wherein R^7 is selected from the group consisting of C_4 to C_{20} alkyl, C_4 to C_{20} alkenyl, (C_1 - C_{10} alkyl)phenyl, and phenyl (C_1 to C_{10} alkyl) and wherein R^8 is C_1 - C_4 alkyl.

62. (New) The composition of claim 22, wherein R^7 is C_4 - C_{20} alkyl and wherein R^8 is C_1 - C_4 alkyl.

63. (New) The composition of claim 22, wherein R^7 is not substituted or interrupted and wherein R^8 is C_1 - C_4 alkyl.

64. (New) The composition of claim 22, wherein R^7 is selected from the group consisting of C_4 to C_{20} alkyl, C_4 to C_{20} alkenyl, (C_1 - C_{10} alkyl)phenyl, and phenyl (C_1 to C_{10} alkyl).

65. (New) The composition of claim 22, wherein R^7 is C_4 - C_{20} alkyl.

66. (New) The composition of claim 22, wherein R^7 is not substituted or interrupted.

67. (New) The composition of claim 22, wherein R^8 is hydrogen.

68. (New) The composition of claim 22, wherein R^8 is C_1 - C_4 alkyl.

69. (New) The composition of claim 22, wherein the biologically active agent is a peptide.

70. (New) The composition of claim 22, wherein the biologically active agent is a mucopolysaccharide.

71. (New) The composition of claim 23, wherein R^7 is not substituted or interrupted and wherein R^8 is hydrogen.

72. (New) The composition of claim 23, wherein R^7 is not substituted or interrupted and wherein R^8 is C_1 - C_4 alkyl.

73. (New) The composition of claim 23, wherein R^7 is not substituted or interrupted.

74. (New) The composition of claim 23, wherein R^8 is hydrogen.
75. (New) The composition of claim 23, wherein R^8 is C_1 - C_4 alkyl.
76. (New) The composition of claim 23, wherein the biologically active agent is a peptide.
77. (New) The composition of claim 23, wherein the biologically active agent is a mucopolysaccharide.
78. (New) The composition of claim 24, wherein R^7 is selected from the group consisting of C_4 to C_{20} alkyl, C_4 to C_{20} alkenyl, (C_1 - C_{10} alkyl)phenyl, and phenyl (C_1 to C_{10} alkyl) and wherein R^8 is hydrogen..
79. (New) The composition of claim 24, wherein R^7 is C_4 - C_{20} alkyl and wherein R^8 is hydrogen.
80. (New) The composition of claim 24, wherein R^7 is not substituted or interrupted and wherein R^8 is hydrogen.

81. (New) The composition of claim 24, wherein R^7 is selected from the group consisting of C_4 to C_{20} alkyl, C_4 to C_{20} alkenyl, $(C_1-C_{10}$ alkyl)phenyl, and phenyl (C_1 to C_{10} alkyl) and wherein R^8 is C_1-C_4 alkyl.

82. (New) The composition of claim 24, wherein R^7 is C_4-C_{20} alkyl and wherein R^8 is C_1-C_4 alkyl.

83. (New) The composition of claim 24, wherein R^7 is not substituted or interrupted and wherein R^8 is C_1-C_4 alkyl.

84. (New) The composition of claim 24, wherein R^7 is selected from the group consisting of C_4 to C_{20} alkyl, C_4 to C_{20} alkenyl, $(C_1-C_{10}$ alkyl)phenyl, and phenyl (C_1 to C_{10} alkyl).

85. (New) The composition of claim 24, wherein R^7 is C_4-C_{20} alkyl.

86. (New) The composition of claim 24, wherein R^7 is not substituted or interrupted.

87. (New) The composition of claim 24, wherein R^8 is hydrogen.

88. (New) The composition of claim 24, wherein R^8 is C_1-C_4 alkyl.

89. (New) The composition of claim 24, wherein the biologically active agent is a peptide.
90. (New) The composition of claim 24, wherein the biologically active agent is a mucopolysaccharide.
91. (New) The composition of claim 25, wherein R^7 is not substituted or interrupted.
92. (New) The composition of claim 25, wherein R^7 is not substituted or interrupted and wherein R^8 is C_1 - C_4 alkyl.
93. (New) The composition of claim 25, wherein R^7 is not substituted or interrupted and wherein R^8 is hydrogen.
94. (New) The composition of claim 25, wherein R^8 is hydrogen.
95. (New) The composition of claim 25, wherein R^8 is C_1 - C_4 alkyl.
96. (New) The composition of claim 25, wherein the biologically active agent is a peptide.

97. (New) The composition of claim 25, wherein the biologically active agent is a mucopolysaccharide.

98. (New) The composition of claim 26, wherein R^8 is hydrogen.

99. (New) The composition of claim 26, wherein R^8 is C_1 - C_4 alkyl.

100. (New) The composition of claim 26, wherein the biologically active agent is a peptide.

101. (New) The composition of claim 26, wherein the biologically active agent is a mucopolysaccharide.

102. (New) The composition of claim 27, wherein R^8 is C_1 - C_4 alkyl.

103. (New) The composition of claim 27, wherein the biologically active agent is a peptide.

104. (New) The composition of claim 27, wherein the biologically active agent is a mucopolysaccharide.

112. (New) The dosage unit form according to claim 41, wherein Ar is a phenyl substituted with -Cl.

113. (New) The dosage unit form according to claim 41, wherein R⁸ is hydrogen.

114. (New) The dosage unit form according to claim 41, wherein R⁸ is C₁-C₄ alkyl.

115. (New) The dosage unit form according to claim 41, wherein said biologically active agent comprises at least one peptide, hormone, polysaccharide, mucopolysaccharide, carbohydrate, or lipid.

116. (New) The dosage unit form according to claim 41, wherein said biologically active agent is a peptide.

117. (New) The dosage unit form according to claim 41, wherein said biologically active agent is a mucopolysaccharide.

118. (New) The dosage unit form according to claim 41, wherein said biologically active agent comprises human growth hormone, bovine growth hormone, growth hormone-releasing hormone, an interferon, interleukin-1, interleukin-II, insulin, heparin, low

molecular weight heparin, calcitonin, erythropoietin, atrial naturetic factor, an antigen, a monoclonal antibody, somatostatin, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, vasopressin, cromolyn sodium, vancomycin, desferrioxamine, parathyroid hormone, an antimicrobial, an antifungal agent or a combination thereof.

119. (New) The dosage unit form according to claim 41, wherein Ar is a phenyl substituted with -F.

120. (New) The dosage unit form according to claim 41, wherein R⁷ is selected from the group consisting of C₄ to C₂₀ alkyl, C₄ to C₂₀ alkenyl, (C₁-C₁₀ alkyl)phenyl, and phenyl (C₁ to C₁₀ alkyl).

121. (New) The dosage unit form according to claim 41, wherein R⁷ is C₄-C₂₀ alkyl.

122. (New) The dosage unit form according to claim 41, wherein R⁷ is not substituted or interrupted.

123. (New) The dosage unit form according to claim 41, comprising a tablet.

124. (New) The dosage unit form according to claim 41, comprising a capsule.
125. (New) The method according to claim 44, wherein the biologically active agent comprises at least one peptide, hormone, polysaccharide, mucopolysaccharide, carbohydrate, or lipid.
126. (New) The method according to claim 44, wherein the biologically active agent is a peptide.
127. (New) The method according to claim 44, wherein the biologically active agent is a mucopolysaccharide.
128. (New) The method according to claim 44, wherein the biologically active agent comprises human growth hormone, bovine growth hormone, growth hormone-releasing hormone, an interferon, interleukin-1, interleukin-II, insulin, heparin, low molecular weight heparin, calcitonin, erythropoietin, atrial naturetic factor, an antigen, a monoclonal antibody, somatostatin, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, vasopressin, cromolyn sodium, vancomycin, desferrioxamine, parathyroid hormone, an antimicrobial, an antifungal agent or a combination thereof.

129. (New) The method according to claim 44, wherein said biologically-active agent comprises human growth hormone, an interferon, insulin, heparin, low molecular weight heparin, calcitonin, erythropoietin, cromolyn sodium, parathyroid hormone, an antimicrobial or a combination thereof.

130. (New) The method according to claim 44, wherein said biologically-active agent comprises human growth hormone.

131. (New) The method according to claim 44, wherein said biologically-active agent comprises insulin.

132. (New) The method according to claim 44, wherein said biologically-active agent comprises heparin.

133. (New) The method according to claim 44, wherein said biologically-active agent comprises low molecular weight heparin.

134. (New) The method according to claim 44, wherein said biologically-active agent comprises calcitonin.

135. (New) The method according to claim 44, wherein said biologically-active agent comprises cromolyn sodium.

136. (New) The method according to claim 44, wherein said biologically-active agent comprises parathyroid hormone.

137. (New) The method according to claim 44, wherein said biologically-active agent comprises interferon.

138. (New) The method according to claim 44, wherein said biologically-active agent comprises erythropoietin.

139. (New) The method according to claim 44, wherein said biologically-active agent comprises an antigen.

140. (New) The method according to claim 44, wherein said biologically-active agent comprises an antimicrobial.

141. (New) The method according to claim 44, wherein Ar is a phenyl substituted with at least one of C₁-C₅ alkyl, C₂-C₄ alkenyl, -F, -Cl, -OH, -SO₂, -COOH or -SO₃H.

142. (New) The method according to claim 44, wherein Ar is a phenyl substituted with -Cl.

143. (New) The method according to claim 44, wherein Ar is a phenyl substituted with -F.

144. (New) The method according to claim 44, wherein R⁷ is selected from the group consisting of C₄ to C₂₀ alkyl, C₄ to C₂₀ alkenyl, (C₁-C₁₀ alkyl)phenyl, and phenyl (C₁ to C₁₀ alkyl).

145. (New) The method according to claim 44, wherein R⁷ is C₄-C₂₀ alkyl.

146. (New) The method according to claim 44, wherein R⁷ is not substituted or interrupted.

147. (New) The method according to claim 44, wherein R⁸ is hydrogen.

148. (New) The method according to claim 44, wherein R⁸ is C₁-C₄ alkyl.

149. (New) The method according to claim 45, wherein the biologically active agent comprises at least one peptide, hormone, polysaccharide, mucopolysaccharide, carbohydrate, or lipid.

150. (New) The method according to claim 45, wherein the biologically active agent is a peptide.

151. (New) The method according to claim 45, wherein the biologically active agent is a mucopolysaccharide.

152. (New) The method according to claim 45, wherein the biologically active agent comprises human growth hormone, bovine growth hormone, growth hormone-releasing hormone, an interferon, interleukin-1, interleukin-II, insulin, heparin, low molecular weight heparin, calcitonin, erythropoietin, atrial natriuretic factor, an antigen, a monoclonal antibody, somatostatin, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, vasopressin, cromolyn sodium, vancomycin, desferrioxamine, parathyroid hormone, an antimicrobial, an antifungal agent or a combination thereof.

153. (New) The method according to claim 45, wherein said biologically-active agent comprises human growth hormone, an interferon, insulin, heparin, low molecular weight heparin, calcitonin, erythropoietin, cromolyn sodium, parathyroid hormone, an antimicrobial or a combination thereof.

154. (New) The method according to claim 45, wherein said biologically-active agent comprises human growth hormone.

155. (New) The method according to claim 45, wherein said biologically-active agent comprises insulin.

156. (New) The method according to claim 45, wherein said biologically-active agent comprises heparin.

157. (New) The method according to claim 45, wherein said biologically-active agent comprises low molecular weight heparin.

158. (New) The method according to claim 45, wherein said biologically-active agent comprises calcitonin.

159. (New) The method according to claim 45, wherein said biologically-active agent comprises cromolyn sodium.

160. (New) The method according to claim 45, wherein said biologically-active agent comprises parathyroid hormone.

161. (New) The method according to claim 45, wherein said biologically-active agent comprises interferon.

162. (New) The method according to claim 45, wherein said biologically-active agent comprises erythropoietin.

163. (New) The method according to claim 45, wherein said biologically-active agent comprises an antigen.

164. (New) The method according to claim 45, wherein said biologically-active agent comprises an antimicrobial.

165. (New) The method according to claim 45 wherein Ar is a phenyl substituted with at least one of C₁-C₅ alkyl, C₂-C₄ alkenyl, -F, -Cl, -OH, -SO₂, -COOH or -SO₃H.

166. (New) The method according to claim 45, wherein Ar is a phenyl substituted with -Cl.

167. (New) The method according to claim 45, wherein Ar is a phenyl substituted with -F.

168. (New) The method according to claim 45, wherein R⁷ is selected from the group consisting of C₄ to C₂₀ alkyl, C₄ to C₂₀ alkenyl (C₁-C₁₀ alkyl)phenyl, and phenyl (C₁ to C₁₀ alkyl).

169. (New) The method according to claim 45, wherein R⁷ is C₄-C₂₀ alkyl.

170. (New) The method according to claim 45, wherein R⁷ is not substituted or interrupted.

171. (New) The method according to claim 45, wherein R⁸ is hydrogen.

172. (New) The method according to claim 45, wherein R⁸ is C₁-C₄ alkyl.

173. (New) The method according to claim 46, wherein the biologically active agent comprises at least one peptide, hormone, polysaccharide, mucopolysaccharide, carbohydrate, or lipid.

174. (New) The method according to claim 46, wherein the biologically active agent is a peptide.

175. (New) The method according to claim 46, wherein the biologically active agent is a mucopolysaccharide.

176. (New) The method according to claim 46, wherein the biologically active agent comprises human growth hormone, bovine growth hormone, growth hormone-releasing hormone, an interferon, interleukin-1, interleukin-II, insulin, heparin, low molecular weight heparin, calcitonin, erythropoietin, atrial natriuretic factor, an antigen, a monoclonal antibody, somatostatin, adrenocorticotropin, gonadotropin releasing hormone, oxytocin,

vasopressin, cromolyn sodium, vancomycin, desferrioxamine, parathyroid hormone, an antimicrobial, an antifungal agent or a combination thereof.

177. (New) The method according to claim 46, wherein said biologically-active agent comprises human growth hormone, an interferon, insulin, heparin, low molecular weight heparin, calcitonin, erythropoietin, cromolyn sodium, parathyroid hormone, an antimicrobial or a combination thereof.

178. (New) The method according to claim 46, wherein said biologically-active agent comprises human growth hormone.

179. (New) The method according to claim 46, wherein said biologically-active agent comprises insulin.

180. (New) The method according to claim 46, wherein said biologically-active agent comprises heparin.

181. (New) The method according to claim 46, wherein said biologically-active agent comprises low molecular weight heparin.

182. (New) The method according to claim 46, wherein said biologically-active agent comprises calcitonin.

183. (New) The method according to claim 46, wherein said biologically-active agent comprises cromolyn sodium.

184. (New) The method according to claim 46, wherein said biologically-active agent comprises parathyroid hormone.

185. (New) The method according to claim 46, wherein said biologically-active agent comprises interferon.

186. (New) The method according to claim 46, wherein said biologically-active agent comprises erythropoietin.

187. (New) The method according to claim 46, wherein said biologically-active agent comprises an antigen.

188. (New) The method according to claim 46, wherein said biologically-active agent comprises an antimicrobial.

189. (New) The method according to claim 46 wherein Ar is a phenyl substituted with at least one of C₁-C₃ alkyl, C₂-C₄ alkenyl, -F, -Cl, -OH, -SO₂, -COOH or -SO₃H.

190. (New) The method according to claim 46, wherein Ar is a phenyl substituted with -Cl.

191. (New) The method according to claim 46, wherein Ar is a phenyl substituted with -F.

192. (New) The method according to claim 46, wherein R⁷ is selected from the group consisting of C₄ to C₂₀ alkyl, C₄ to C₂₀ alkenyl (C₁-C₁₀ alkyl)phenyl, and phenyl (C₁ to C₁₀ alkyl).

193. (New) The method according to claim 46, wherein R⁷ is C₄-C₂₀ alkyl.

194. (New) The method according to claim 46, wherein R⁷ is not substituted or interrupted.

195. (New) The method according to claim 46, wherein R⁸ is hydrogen.

196. (New) The method according to claim 46, wherein R⁸ is C₁-C₄ alkyl.

197. (New) A method for administering a biologically-active agent to a human in need of said agent, said method comprising administering orally to said human a composition as defined in claim 21.

198. (New) The method according to claim 197, wherein the biologically active agent comprises at least one peptide, hormone, polysaccharide, mucopolysaccharide, carbohydrate, or lipid.

199. (New) The method according to claim 197, wherein the biologically active agent is a peptide.

200. (New) The method according to claim 197, wherein the biologically active agent is a mucopolysaccharide.

201. (New) The method according to claim 197, wherein the biologically active agent comprises human growth hormone, bovine growth hormone, growth hormone-releasing hormone, an interferon, interleukin-1, interleukin-II, insulin, heparin, low molecular weight heparin, calcitonin, erythropoietin, atrial naturetic factor, an antigen, a monoclonal antibody, somatostatin, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, vasopressin, cromolyn sodium, vancomycin, desferrioxamine, parathyroid hormone, an antimicrobial, an antifungal agent or a combination thereof.

202. (New) The method according to claim 197, wherein said biologically-active agent comprises human growth hormone, an interferon, insulin, heparin, low molecular weight heparin, calcitonin, erythropoietin, cromolyn sodium, parathyroid hormone, an antimicrobial or a combination thereof.

203. (New) The method according to claim 197, wherein said biologically-active agent comprises human growth hormone.

204. (New) The method according to claim 197, wherein said biologically-active agent comprises insulin.

205. (New) The method according to claim 197, wherein said biologically-active agent comprises heparin.

206. (New) The method according to claim 197, wherein said biologically-active agent comprises low molecular weight heparin.

207. (New) The method according to claim 197, wherein said biologically-active agent comprises calcitonin.

208. (New) The method according to claim 197, wherein said biologically-active agent comprises cromolyn sodium.

209. (New) The method according to claim 197, wherein said biologically-active agent comprises parathyroid hormone.

210. (New) The method according to claim 197, wherein said biologically-active agent comprises interferon.

211. (New) The method according to claim 197, wherein said biologically-active agent comprises erythropoietin.

212. (New) The method according to claim 197, wherein said biologically-active agent comprises an antigen.

213. (New) The method according to claim 197, wherein said biologically-active agent comprises an antimicrobial.

214. (New) The method according to claim 197 wherein Ar is a phenyl substituted with at least one of C₁-C₃ alkyl, C₂-C₄ alkenyl, -F, -Cl, -OH, -SO₂, -COOH or -SO₃H.

215. (New) The method according to claim 197, wherein Ar is a phenyl substituted with -Cl.

216. (New) The method according to claim 197, wherein Ar is a phenyl substituted with -F.

217. (New) The method according to claim 197, wherein R^7 is selected from the group consisting of C_4 to C_{20} alkyl, C_4 to C_{20} alkenyl, $(C_1-C_{10}$ alkyl)phenyl, and phenyl (C_1 to C_{10} alkyl).

218. (New) The method according to claim 197, wherein R^7 is C_4-C_{20} alkyl.

219. (New) The method according to claim 197, wherein R^7 is not substituted or interrupted.

220. (New) The method according to claim 197, wherein R^8 is hydrogen.

221. (New) The method according to claim 197, wherein R^8 is C_1-C_4 alkyl.